4-[3-(Dimethylamino)-1,2,4-oxadiazol-5-yl]-2,6-bis(1,1-dimethylethyl)phenol | 130116-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[3-(Dimethylamino)-1,2,4-oxadiazol-5-yl]-2,6-bis(1,1-dimethylethyl)phenol
• 英文别名: 2,6-ditert-butyl-4-[3-(dimethylamino)-1,2,4-oxadiazol-5-yl]phenol
• CAS: 130116-58-4
• 化学式: C₁₈H₂₇N₃O₂
• 分子量: 317.431
• InChiKey: CFGIPOLINHGGNP-UHFFFAOYSA-N

物化性质

• 沸点：
  403.0±55.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  62.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 4-(3-Amino-[1,2,4]oxadiazol-5-yl)-2,6-di-tert-butyl-phenol 在 sodium cyanoborohydride 作用下， 以 溶剂黄146 为溶剂， 反应 24.0h， 以46%的产率得到4-[3-(Dimethylamino)-1,2,4-oxadiazol-5-yl]-2,6-bis(1,1-dimethylethyl)phenol
  参考文献：
  名称：

  Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors

  摘要：

  A series of 1,2,4-oxadiazoles and 1,2,4-thiadiazoles containing a 2,6-di-tert-butylphenol substituent were prepared and evaluated as dual inhibitors of 5-lipoxygenase and cyclooxygenase in rat basophilic leukemia (RBL-1) cells. Several of these compounds show oral efficacy in the rat carageenan footpad edema (CFE) and mycobacterium footpad edema (MFE) antiinflammatory models, without concomitant gastric ulceration. Structure-activity relationships are discussed. The best compounds (ID40 values in MFE of 3-8 mg/kg po) contain guanidine-derived substituents on the heterocyclic ring.

  DOI：

  10.1021/jm00098a015

文献信息

• 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and
  申请人：Warner-Lambert Company

  公开号：US05155122A1

  公开（公告）日：1992-10-13

  The present invention is novel compounds which are 3,5-di-tertiary-butyl-4-hydroxyphenyl substituted 1,2,4- and 1,3,4-thiadazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.

  本发明涉及新型化合物，其为3,5-二叔丁基-4-羟基苯基取代的1,2,4-和1,3,4-噻二唑和噁二唑以及1,2,4-三唑，以及其药学上可接受的加合物和碱盐、制药组合物和使用方法。现发现该发明化合物具有作为5-脂氧合酶和/或环氧合酶抑制剂的活性，从而提供治疗因此类抑制而受益的疾病的方法，包括炎症、关节炎、疼痛、发热等。
• 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0371438A2

  公开（公告）日：1990-06-06

  The present invention is novel compounds which are 3,5-di-tertiary-butyl-4-hydroxyphenyl substituted 1,2,4-and 1,3,4-thiadazoles and oxadiazoles, and 1,2,4-triazoles, and pharmaceutically acceptable additions and base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.

  本发明是3,5-二叔丁基-4-羟基苯基取代的1,2,4和1,3,4-噻二唑和噁二唑以及1,2,4-三唑的新型化合物及其药学上可接受的添加剂和基盐、药物组合物和使用方法。现在发现，本发明化合物具有作为 5-脂氧合酶和/或环氧合酶抑制剂的活性，可治疗受这种抑制影响的有利病症，包括炎症、关节炎、疼痛、发热等。
• US5155122A
  申请人：——

  公开号：US5155122A

  公开（公告）日：1992-10-13
• US5376670A
  申请人：——

  公开号：US5376670A

  公开（公告）日：1994-12-27
• Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors
  作者：Paul C. Unangst、Gary P. Shrum、David T. Connor、Richard D. Dyer、Denis J. Schrier

  DOI：10.1021/jm00098a015

  日期：1992.10

  A series of 1,2,4-oxadiazoles and 1,2,4-thiadiazoles containing a 2,6-di-tert-butylphenol substituent were prepared and evaluated as dual inhibitors of 5-lipoxygenase and cyclooxygenase in rat basophilic leukemia (RBL-1) cells. Several of these compounds show oral efficacy in the rat carageenan footpad edema (CFE) and mycobacterium footpad edema (MFE) antiinflammatory models, without concomitant gastric ulceration. Structure-activity relationships are discussed. The best compounds (ID40 values in MFE of 3-8 mg/kg po) contain guanidine-derived substituents on the heterocyclic ring.